NRBO NeuroBo Pharmaceuticals Inc.

FDA Catalyst Company
0.57
+0.03  (+6%)
Previous Close 0.54
Open 0.57
52 Week Low 0.4134
52 Week High 6.57
Market Cap $15,197,209
Shares 26,661,771
Float 13,593,381
Enterprise Value $-2,739,827
Volume 11,825
Av. Daily Volume 223,725
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
HC Wainwright & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 02/01/2021

Latest News

  1. BOSTON, May 6, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced the appointment, effective April 30, 2022 of Matthew Bardin, PharmD, BCPS as Senior Vice President, Operations. Reporting directly to President and Chief Executive Officer, Gil Price, M.D., Dr. Bardin will be responsible for day to day operations, with a focus on clinical development.

    "Matthew is a highly experienced pharmaceutical professional who brings to NeuroBo an extensive track record of clinical drug development, medical affairs and oversight expertise in a number of therapeutic areas, most importantly within the area of infectious diseases and gastroenterology," stated Gil Price, M.D., President and…

    View Full Article
  2. BOSTON, April 1, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced financial results for the year ended December 31, 2021.

    Management Commentary

    "Since I joined NeuroBo in November of 2021, we have had the opportunity to significantly strengthen our team including the addition of highly accomplished executive, D. Gordon Strickland, to our Board of Directors in January and, most recently, with the appointment of Danamarie Belpulsi, M.D. to our Scientific Advisory Board. Their collective experience will be invaluable as we continue to move programs through the clinic," stated Gil Price, M.D. President and Chief Executive Officer of NeuroBo. 

    "Also of note, following a positive…

    View Full Article
  3. BOSTON, March 15, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced the appointment, effective immediately, of Danamarie Belpulsi, M.D., to its Scientific Advisory Board.

    "Dr. Belpulsi brings to NeuroBo extensive expertise within a number of highly relevant areas including infectious diseases, cardiology and neurology, to name a few," stated Gil Price, M.D., President and Chief Executive Officer of NeuroBo. "Additionally, her deep experience in the area of clinical trial research and her strong relationships with key opinion leaders, will be important as we move programs through the clinic, going forward."

    "I am delighted to join NeuroBo's Scientific Advisory Board," stated…

    View Full Article
  4. BOSTON, Jan. 28, 2022 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company, today announced the appointment of D. Gordon Strickland to its Board of Directors, effective as of January 27, 2022. Mr. Strickland will serve as Chair of the Company's Audit Committee.

    "Gordon is a highly accomplished executive with more than 35 years of experience, including many senior leadership positions," said Andrew I. Koven, Chairman of NeuroBo's Board of Directors. "I am pleased to welcome him to the NeuroBo Board of Directors and look forward to his contributions as we pursue our next phase of growth and development."

    "I am excited to join the NeuroBo Board of Directors at such an important stage for the Company…

    View Full Article
  5. BOSTON, Nov. 15, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2021.

    Third Quarter Highlights

    "In October, following a positive recommendation from the independent data safety monitoring board, we continued to advance our phase 2/3 clinical trial of lead drug candidate, ANA001, a proprietary oral niclosamide formulation, in development as a treatment for patients with moderate to severe COVID-19," stated Richard J. Kang, Ph.D., outgoing President and Chief Executive Officer of…

    View Full Article
View All NeuroBo Pharmaceuticals Inc. News